{'fraction_non_alphanumeric': 0.037238169123351435, 'fraction_numerical': 0.035686578743211794, 'mean_word_length': 5.262135922330097, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The role of lncRNAKCNQ1OT1/miR-301b/Tcf7 Axis in Cardiac Hypertrophy


 Cardiac hypertrophy, acting as a pathologic progress of chronic hypertension and coronary disease. Increasing evidence indicates that lncRNA potassium voltage-gated channel subfamily q member 1 overlapping transcript 1 (KCNQ1OT1) may led to MI. Recent studies showed, miR-301b level was evidently decreased in heart failure patients. To explore the regulate effect of lncRNAKCNQ1OT1 and miR-301b in cardiac hypertrophy, gain-and-lose function assays were tested. Notably, lncRNAKCNQ1OT1 overexpression causes a significant result as cardiac hypertrophy. Furthermore, lncRNAKCNQ1OT1 sponge microRNA-301b. The results showed that miR-301b exhibited lower expression in cardiac hypertrophy model, indicating that it may exert anti-hypertrophic role. Furthermore, the BNP and β-MHC expression increased, as well as cardiomyocyte surface area, with Ang II treatment, while the effect was repealed by miR-301b. Moreover, the protein expression of Tcf7 was down-regulated or up-regulated by miR-301b or AMO-301b. As displayed by luciferase reporter assay, miR-301b binds to 3’UTR of Tcf7. Briefly, we aimed to elucidate a down-regulate role of miR-301b in cardiac hypertrophy, as to provide potential therapeutic strategies.